NCT02955940 2025-12-17An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte CorporationPhase 2 Active not recruiting10 enrolled
NCT02119650 2018-02-13Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerIncyte CorporationPhase 2 Terminated76 enrolled 13 charts